Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective.

Tana Saiyin, Grace Christou, Mitchell Sabloff, Tina Crosbie, Kim-My Nguyen-Tham, Jill Fulcher

Abstract read

In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.Current oncology (Toronto, Ont.) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tana SaiyinDepartment of Medicine, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

Grace ChristouThe Ottawa Hospital Leukemia Program, Department of Medicine, Division of Hematology, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

Mitchell SabloffThe Ottawa Hospital Leukemia Program, Department of Medicine, Division of Hematology, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-0122-6138

Tina CrosbieDepartment of Pharmacy, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.ORCID 0009-0001-3932-1456

Kim-My Nguyen-ThamDepartment of Pharmacy, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

Jill FulcherThe Ottawa Hospital Leukemia Program, Department of Medicine, Division of Hematology, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-0369-5034

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azacitidine and venetoclax (Aza-Ven) are part of a new standard of care for elderly patients with Acute Myeloid Leukemia (AML) [In line with recommendations, patients with AML at our centre were routinely admitted during initiation of Aza-Ven for close monitoring for tumour lysis syndrome (TLS). However, hospitalization impacts patient experience and is a significant resource burden. The objectives of this study were to evaluate the incidence of TLS in this population and identify patients who could safely initiate therapy in our outpatient facility. Of the 48 patients who commenced Aza-Ven as inpatients, the incidence of TLS was 25% using Cairo-Bishop (CB) diagnostic criteria but was mostly due to transient increases in uric acid, phosphate or potassium that remained within the normal laboratory reference range. Using Howard diagnostic criteria, TLS incidence was only 2%. Patients who developed CB TLS had a significantly higher baseline white blood count (WBC;

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesTumor Lysis SyndromeAgedAged, 80 and overCanadaFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxacute myeloid leukemiaazacitidinetumour lysis syndromevenetoclax

Identifiers

PMID40277769

DOI10.3390/curroncol32040213

PMCPMC12026339

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.